R&D
Rooted in distinctive platform technology based on strong medicinal chemistry expertise, LCB is a global biotechnology company dedicated to drug discovery and development
Research Area
Leveraging medicinal chemistry expertise,
Devoted to revolutionary new drug discovery and development, and
Focused on ADC and small molecule drugs in oncology, immuno-oncology, antibiotics and antifibrotics with significant global unmet needs
Devoted to revolutionary new drug discovery and development, and
Focused on ADC and small molecule drugs in oncology, immuno-oncology, antibiotics and antifibrotics with significant global unmet needs
ADC
Antibody-Drug Conjugates
Antibody-Drug Conjugates (ADCs) are a novel class of highly potent drugs built by attaching a small molecule anticancer drug or another therapeutic agent to an antibody with a linker.
Using the antibody's property to target a specific antigen only found on target cells, the ADCs deliver the highly potent drugs with a very high specificity to the cancer cells, maximizing the efficacy and minimizing systemic exposure with associated side effects.
solid cancer
hematological cancer
NCE
Small molecule based drug
Over 30 years of experience and expertise compiled in medicinal chemistry, LCB uses its proprietary drug-like compounds, namely, 'building blocks' to accelerate drug discovery research.
Immuno Oncology
Anti-infectives
Anti-fibrotics